Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 26, Issue 21, 2008, Pages 3598-3606

  Krivak, Thomas C ^a   Darcy, Kathleen M ^a   Tian, Chunqiao ^a   Armstrong, Deborah ^a   Baysal, Bora E ^a   Gallion, Holly ^a   Ambrosone, Christine B ^a   DeLoia, Julie A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CODON; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM; OVARY TUMOR; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 49049118079     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.1323     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 58:71-96, 2008
2. Colombo N, Van Gorp T, Parma G, et al: Ovarian cancer. Crit Rev Oncol Hematol 60:159-179, 2006
3. Bhoola S, Hoskins WJ: Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 107:1399-1410, 2006
4. Bookman MA: Standard treatment in advanced ovarian cancer in 2005: The state of the art. Int J Gynecol Cancer 15:212-220, 2005 (suppl 3)
5. Berkenblit A, Cannistra SA: Advances in the management of epithelial ovarian cancer. J Reprod Med 50:426-438, 2005
6. Muggia FM: Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. Semin Oncol 31:19-24, 2004
7. Ozols RF: Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer. Cancer Invest 22:11-20, 2004
8. Hoskins WJ, Bundy BN, Thigpen JT, et al: The influence on cytoreductive surgery on recurrence free interval and survival in small volume stage III epithelial ovarian cancer: A Gynecologic Oncology group study. Gynecol Oncol 47:159-166, 1992
9. Hoskins WJ, McGuire WP, Brady MF, et al: The effect of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual ovarian carcinoma. Am J Obstet Gynecol 170:974-979, 1994
10. McGuire V, Jesser CA, Whittmore AS: Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 84:399-403, 2002
11. Armstrong DK: Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist 7:20-28, 2002
12. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996
13. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: An intergroup study of the GOG, SWOG, and ECOG. J Clin Oncol 19:1001-1007, 2001
14. Armstrong DK, Bundy BN, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
15. Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002
16. Joshi MBM, Shirota Y, Danenberg KD, et al: High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients with trimodality therapy for esophageal cancer. Clin Cancer Res 11:2215-2221, 2005
17. Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818-1825, 2006
18. Bellmunt J, Paz-Ares L, Cuello M, et al: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18:522-528, 2007
19. Dabholkar M, Vionnet J, Bostick-Bruton F, et al: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94:703-708, 1994
20. Selvakumaran M, Pisarcik DA, Bao R, et al: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63:1311-1316, 2003
21. Yu JJ, Lee KB, Mu C, et al: Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16:555-560, 2000
22. Moreno V, Gemignani F, Landi S, et al: Polymorphisms in genes of nucleotide and base excision repair: Risk and prognosis of colorectal cancer. Clin Cancer Res 12:2101-2108, 2006
23. Park DJ, Zhang W, Stoehlmacher J, et al: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1:162-166, 2003
24. Viguier J, Boige V, Miquel C, et al: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaxiplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11:6212-6217, 2005
25. Liu D, O'Day SJ, Yang D, et al: Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: An exploratory study. Clin Cancer Res 11:1237-1246, 2005
26. Zhou W, Gurubhagavatula S, Liu G, et al: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939-4943, 2004
27. Kang S, Ju W, Kim JW, et al: Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38:320-324, 2006
28. Chen P, Wiencke J, Aldape K, et al: Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9:843-847, 2000
29. Quintela-Fandino M, Hitt R, Medina PP, et al: DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24:4333-4339, 2006
30. Baysal BE, DeLoia JA, Willett-Brozick JE, et al: Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol 95:62-69, 2004
31. Winter WE, Maxwell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:3621-3627, 2007
32. Zhou W, Liu G, Park S, et al: Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 14:491-496, 2005
33. Stoehlmacher J, Park DJ, Zhang W, et al: A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354, 2004
34. Ryu JS, Hong YC, Han HS, et al: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44:311-316, 2004
35. Isla D, Sarries C, Rosell R, et al: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194-1203, 2004
36. Smith S, Su D, Rigault de la Longrais IA, et al: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25:5172-5179, 2007
37. Marsh S, Paul J, King CR, et al: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25:4528-4535, 2007